ClinicalTrials.gg
CompletedNCT03941340Updated Jan 6, 2020

Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers

A Phase 1 interventional study of [14]-AST2818 in Healthy Male Volunteers, sponsored by Allist Pharmaceuticals, Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-06.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers

Read the detailed description

A Phase I Mass Balance and Biotransformation Study of Orally Administered [14C]-Alflutinib Mesylate (AST2818) in Chinese Healthy Male Volunteers

02

Conditions studied

  • Healthy Male Volunteers
03

In context

Lead sponsor

Allist Pharmaceuticals, Inc. is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult;
  2. Body weight: The varies in the range of 19 - 26 kg/m2 (including 19 and 26 kg/m2);
  3. Signing the forms by oneself ;
  4. Be able to communicate well with the researcher and be able to complete the trial in accordance with the program.

Exclusion criteria

Exclusion Criteria:

  1. Those with abnormal examination and clinical significance ( including Physical examination, routine laboratory examination (blood routine, urine routine, fecal routine + Occult blood, blood biochemistry, blood coagulation routine, thyroid function), 12-lead , X-ray (positive position), abdominal B-mode ultrasonography (liver, gallbladder, pancreas, spleen and kidney), etc);
  2. Those with routine urine examination showed positive urinary protein;
  3. Those with > 470 msec in resting state, corrected by ECG during screening period;
  4. Those with , HBeAg and HCVAb were positive;
  5. Those with HIVAb was positive;
  6. Those with treponema pallidum Ab was positive;
  7. Those who take any drugs that inhibit or induce the CYP450 enzyme (i.e., inducers- barbiturates, tegretol, phenytoin, rifampicin, hexadecadrol, rifabutin, rifapentini; inhibitors- SSRI-antidepressant, cimetidine, diltiazem, macrolides, verapamil, imidazoles- antifungal drugs) 30 days prior to screening period;
  8. Those who take any drug, health care products (including vitamins), chinese traditional medicine 14 days prior to screening period;
  9. Those who participated other clinical trials or took the drug 3 months prior to screening period, or prepare to take part in other clinical trials within 1 month after finishing this trial;
  10. Those who have history of organic heart disease, heart failure, myocardial infarction, angina, unexplained arrhythmia, torsional ventricular tachycardia, ventricular tachycardia and QT prolonged syndrome, or have the family history (Genetic proof or a close relative of sudden cardiac death at a young age) and symptom of QT prolonged syndrome ;
  11. Those who have severe disease of ophthalmic system, e.g., corneal, conjunctiva and eyelid diseases;
  12. Those who have undergone major surgery within the first 6 months of the screening period or have no complete surgical incision; major procedures include, but are not limited to, any operator with significant bleeding risk, prolonged general anesthesia, or incisional or significant traumatic injury;
  13. Those who have but not limited to circulatory system, endocrine system, nervous system, digestive system, urinary system, or have the history of blood, immunity spirit and metabolism diseases;
  14. Those who have allergic constitution, including being definitely allergic to TKIs or any ingredients of this trial drugs,any food materials or have special demands for foods,and cannot comply with the rule of unified diet;
  15. Those who have history of hand and foot syndrome;
  16. Those who have haemorrhoids or perianal disease with regular/ongoing hematochezia;
  17. Those who have coagulation dysfunction or other diseases of the blood system;
  18. Those who have history of tumor;
  19. Those who have habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease;
  20. Those who have history of alcohol abuse (it was defined as that the daily alcohol consumption was higher than the following criteria: the weekly alcohol consumption was higher than 14 units of alcohol (1 unit= 360 ml beers/45 ml liquor containing 40% alcohol/150ml grape wine) 6 months prior to screening period, or the alcohol breath test results ≥20 mg/dl during screening period;
  21. Those who smoked daily >5 sticks of cigarette 3 months prior to first dose or cannot give up smoking during study;
  22. Those have history of drug abuse or taking soft drug (i.e., marihuana) 3 months prior to screening period or taking hard drugs (i.e., cocaine, amphetamines, benzodiazepine, etc.); or the results of urine test in drugs were positive;
  23. Those who were used to drink grapefruit juice or overconsumption of tea, coffee, and the drink with caffeine; and cannot give up them during test;
  24. Those who need long-term exposure to radiation, or who have been exposed to significant radiation (> 2 chest/abdominal CT scans or more than 3 other X-ray scans) or who have participated in the labeling test of radiopharmaceuticals within one year before the test;
  25. Those who have fertility planning within the range of starting trial - 1 year after finishing trial, or disagree with the regulation and their mate should take strict (taking condoms, contraceptive sponges, contraceptive gels, contraceptive membranes, intrauterine devices, oral or injectable contraceptives and subcutaneous implants, etc.);
  26. Those who have excessive bleeding or blood donation (400ml) 3 months prior to screening period, or planned to donate blood 1 month after finishing this trial;
  27. Those who cannot complete this study because of other reasons, or any factors judged by investigator that the participants cannot meet.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]-AST2818 80mg (oral solution)

    Volunteers will receive 80 mg \[14C\]-AST2818 containing a nominal 100 μCi activity, administered by mouth, as a solution.

    Drug: [14]-AST2818

Interventions

  • Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1

06

What researchers measure

Primary outcomes

  1. The distribution of AST2818 in the whole blood and plasma and whole radioactive pharmacokinetics following the single orally administered [14C]-AST2818 in healthy male volunteers.

    The percentage of radioactive dose of \[14C\] radiolabelled AST2818 recovered in blood and in total, up to Day 85(p.s:The administration time on the first day is 7:30 am)

    Time frame: Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.

  2. Quantitive analysis of whole radioactivity of excrement of orally administered [14C]-AST2818 in healthy volunteers to obtain the mass balance data and the main excretion pathway in human body.

    The percentage of radioactive dose of \[14C\] radiolabelled AST2818 recovered in urine, faeces and in total, up to Day 85(p.s:The administration time on the first day is 7:30 am)

    Time frame: Urine and faeces (hrs): 0-4, 4-8, 8-12, 12-24, every 24 to 504, 624-672, 792-840, 960-1008, 1128-1176, 1296-1344, 1464-1512, 1632-1680, 1800-1848 and 1968-2016.

  3. Quantitive analysis of the concentrations of AST2818 and AST5902 (Metabolite of AST2818) in plasma using the validated LC-MS/MS to obtain pharmacokinetic data;

    The concentrations of AST2818 and AST5902 in plasma up to Day 85(p.s:The administration time on the first day is 7:30 am)

    Time frame: Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.

  4. Proportion of different metabolites in healthy volunteers after oral administration of [14C]-AST2818

    Proportion of different metabolites

    Time frame: Blood samples (hrs) - 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, every 24 to 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848 and 2016.

  5. Types of adverse events assessed by CTCAE v5.0 that occurred during the trial

    Types of adverse events

    Time frame: Baseline (Day-1) to Day 85(p.s:The administration time on the first day is 7:30 am)

07

Study locations

1 site
  • First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Sep 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
May 7, 2019
StartActual
Apr 8, 2019
Primary completionActual
Sep 6, 2019
CompletionActual
Sep 6, 2019
Last update
Jan 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03941340
Responsible party
Sponsor
First posted
May 7, 2019
Start date
Apr 8, 2019
Primary completion
Sep 6, 2019
Completion
Sep 6, 2019
Last update
Jan 6, 2020

Study contacts

LiYan Miu
principal investigator · First Affiliated Hospital of Soochow University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflutinib

Start the discussion